+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: P08217(DBH Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08217(DBH Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The DNAJB9 antibody targets the DNAJB9 protein, a member of the Hsp40/DnaJ family of molecular chaperones. DNAJB9. also known as ERdj4 or MDG1. functions as a co-chaperone for Hsp70 proteins, aiding in protein folding, quality control, and degradation within the endoplasmic reticulum (ER). It plays a critical role in the unfolded protein response (UPR), helping to alleviate ER stress by binding misfolded proteins and directing them toward ER-associated degradation (ERAD). Dysregulation of DNAJB9 has been implicated in diseases involving protein misfolding, including certain cancers, fibrotic disorders, and neurodegenerative conditions.

In diagnostic contexts, DNAJB9 antibodies are particularly valuable for identifying fibrillary glomerulonephritis (FGN), a rare kidney disease characterized by abnormal glomerular deposits. DNAJB9 immunohistochemistry (IHC) has emerged as a specific marker for FGN, distinguishing it from other amyloidosis or fibrillary-like kidney disorders. Research applications include studying ER stress pathways, tumor progression (e.g., roles in TGF-β signaling and epithelial-mesenchymal transition), and mechanisms underlying fibrosis. Commercially available DNAJB9 antibodies are optimized for techniques like IHC, Western blotting (WB), and immunofluorescence (IF), enabling both clinical diagnostics and molecular studies. Its dual role in proteostasis and disease pathways makes DNAJB9 a protein of growing interest in translational research.